CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Visual analysis of global research on immunotherapy for gastric cancer: A literature mining from 2012 to 2022.
Visual analysis of global research on immunotherapy for gastric cancer: A literature mining from 2012 to 2022.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
胃癌是常见恶性肿瘤,免疫治疗已成为其治疗的重要组成部分。本研究通过文献计量分析梳理胃癌免疫治疗研究现状并寻找潜在方向,使用VOSviewer和CiteSpace展示合作及关联网络。研究纳入2012至2022年1141篇英文文献,发文量逐年增长。文献主要来自中国(579篇,50.70%),其次为美国;复旦大学发文最多(48篇,4.21%)。《Frontiers in Oncology》被引最多,《Journal of Clinical Oncology》共被引最多;Kim Kyoung-Mee发文最多(14篇)。时间线聚类和共被引文献显示研究热点演变:早期集中于细胞因子诱导杀伤细胞和髓源抑制细胞,近年来转向靶向治疗;CAR-T 已成为热点,胃癌研究进入精准治疗阶段。筛选可从免疫治疗获益的患者是改善预后的关键,免疫疗法联合化疗或靶向治疗是当前重点,CAR-T 未来仍将进一步研究。
Gastric cancer (GC) is one of the most common malignancies. Immunotherapy becomes an indispensable part of GC.
This study conducts bibliometric analysis of immunotherapy for GC to clarify the research status and identify potential new research directions. VOS viewer and CiteSpace visualization software were used to demonstrate collaborations and correlations. A total of 1141 English publications from 2012 to 2022 were included. The number of publications increased year by year. The publications were mainly from China ( n = 579, 50. 70%), followed by the United States. Fudan University published the most publications ( n = 48, 4. 21%). Frontiers in Oncology and Journal of Clinical Oncology ranked first in cited and co-cited journals, respectively. Kim Kyoung-Mee published the most publications on immunotherapy for GC ( n = 14). The clustering of timeline view and co-cited references show the hotspot transformation on immunotherapy for GC.
Initially, the hot topic was "cytokine-induced killer cells" and "myeloid-derived suppressor cells." In recent years, the focus has turned to "targeted therapy." "CAR-T" has become the hottest topic, and GC has entered precision therapy phase. Screening patients who can benefit from immunotherapy is key to improving prognosis.
The combination of immunotherapy with other treatment options, such as chemotherapy and targeted therapy, is currently the focus of research. Chimeric antigen receptor T cell will be further studied in the future. Bibliometrics is one of the main tools in the current research and hot spots. Immunotherapy becomes an indispensable part of gastric cancer. Chimeric antigen receptor T cells will play an important role for gastric cancer.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。